Senate Bill No. 741 empowers pharmacists in Oklahoma to test, screen, and initiate drug therapy for minor, nonchronic health conditions under a standing order from a licensed physician or medical director. The bill defines "minor, nonchronic health condition" to include ailments such as influenzas, streptococcus, SARS-CoV-2, and lice, while also stipulating that pharmacists can only use FDA-approved tests and cannot test for streptococcus in children under six years of age.

Additionally, the bill amends the Oklahoma Pharmacy Act by updating terminology to refer to the "State Board of Pharmacy" and clarifying definitions related to pharmacy practice. It introduces new definitions for "nonprescription drugs" and expands the responsibilities of pharmacists to include the ordering, performing, and interpreting of tests for minor, nonchronic health conditions. The bill also revises definitions related to drug packaging, changing the designation of "unit dose package" from 51 to 52 and "unit of issue package" from 52 to 53, with specific labeling requirements for each. The bill is scheduled to take effect on November 1, 2025.

Statutes affected:
Introduced: 59-353.1
Floor (Senate): 59-353.1